Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H20N6O2S |
| Molecular Weight | 468.53 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CN=CC(=C1)C2=NC(NCC3=NC=CC=C3)=C4C(=CC=CC4=N2)C5=CC=CC=C5
InChI
InChIKey=XGKULQQVQWCASY-UHFFFAOYSA-N
InChI=1S/C25H20N6O2S/c26-34(32,33)20-13-18(14-27-16-20)24-30-22-11-6-10-21(17-7-2-1-3-8-17)23(22)25(31-24)29-15-19-9-4-5-12-28-19/h1-14,16H,15H2,(H2,26,32,33)(H,29,30,31)
| Molecular Formula | C25H20N6O2S |
| Molecular Weight | 468.53 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Bristol-Myers Squibb developed BMS-919373, a selective IKur inhibitor for use in atrial fibrillation, acute coronary syndromes, and paroxysmal atrial fibrillation. IKur is a repolarizing K+ current encoded by the KCNA5 gene and is expressed predominantly in the atrium of human. IKur is a potential atrial-selective target for the treatment of atrial fibrillation. BMS-919373 participated in phase II clinical trials to evaluate the effect on atrial fibrillation burden in patients with paroxysmal atrial fibrillation. In addition, in phase I clinical trials for patients with acute coronary syndromes. However, further, developments have been discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:27:35 GMT 2025
by
admin
on
Tue Apr 01 16:27:35 GMT 2025
|
| Record UNII |
NGB50MQK8N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
51030730
Created by
admin on Tue Apr 01 16:27:35 GMT 2025 , Edited by admin on Tue Apr 01 16:27:35 GMT 2025
|
PRIMARY | |||
|
NGB50MQK8N
Created by
admin on Tue Apr 01 16:27:35 GMT 2025 , Edited by admin on Tue Apr 01 16:27:35 GMT 2025
|
PRIMARY | |||
|
BMS-919373
Created by
admin on Tue Apr 01 16:27:35 GMT 2025 , Edited by admin on Tue Apr 01 16:27:35 GMT 2025
|
PRIMARY | MedKoo CAT NO: 522698, CAS NO: 1272353-82-8Description: BMS-919373 is a Potassium channel Kv1.5 (KCNA5) inhibitor for use in atrial fibrillation and acute coronary syndromes. Phase II development is underway in the US and Canada for paroxysmal atrial fibrillation. (last updated: 4/6/2016).Synonym: BMS-919373, BMS 919373, BMS919373. | ||
|
DB15047
Created by
admin on Tue Apr 01 16:27:35 GMT 2025 , Edited by admin on Tue Apr 01 16:27:35 GMT 2025
|
PRIMARY | |||
|
1272353-82-8
Created by
admin on Tue Apr 01 16:27:35 GMT 2025 , Edited by admin on Tue Apr 01 16:27:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Drugs: BMS-919373(Primary), Sotalol; Indication: Atrial fibrillation; Focus: Therapeutic Use; Sponsor: Bristol-Myers Squibb; Most Recent Events: 11 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov record., 11 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov record., 06 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.
|
||
|
ACTIVE MOIETY |
Official Title: A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker
Purpose: To determine the effect of our compound (BMS-919373) on electrical activity of the heart using pacemakers.
|
